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Background: Disease specific, health-related quality of life (HRQoL) measurement is important in cystic fibrosis (CF). This work aimed to
translate the original English Cystic Fibrosis Quality of Life Questionnaire (CFQoL) into Italian, evaluate the linguistic translation and to
psychometrically evaluate the Italian version of the CFQoL.
Methods: The linguistic translation followed the international guidelines of forward and backward translation. Psychometric evaluation of the
Italian CFQoL involved the assessment of construct validity, internal reliability, concurrent validity, known groups validity and test–retest
reliability.
Results: The instrument was acceptable to adolescents and adults with CF and demonstrated robust psychometric properties. Principle
components analysis indicated that the factorial structure was essentially similar to the original, and the internal reliability of each domain
was good (Cronbach alpha coefficients 0.73 to 0.91). Appropriate domains of the CFQoL and SF-36 correlated well indicating good
concurrent validity (r=0.68–0.80). Consistent with theoretical expectations some domains were able to discriminate between disease severity
groups. Test–retest reliability, assessed by intraclass correlation coefficients, was found to be excellent (ICC 0.83 to 0.98).
Conclusions: The Italian CFQoL is a valid and reliable measure. Its use in individual patient monitoring and research should complement
traditional clinical outcome measures.
© 2007 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Health-related quality of life (HRQoL); Linguistic validation; Psychometric validation; Chronic disease1. Introduction
Cystic fibrosis (CF), or mucoviscidosis, is the most
common life-shortening autosomal-recessive disease among
Caucasians, affecting 1 in about 2500 persons, depending on
the country being studied [1], and 1 in 3500–4000 persons in
Italy [2]. Once a tragic, poorly understood condition from
which people died in early childhood, CF is now a serious,⁎ Corresponding author.
E-mail address: francesca.lupi@unibo.it (F. Lupi).
1569-1993/$ - see front matter © 2007 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2007.06.003chronic but treatable disorder, affecting many parts of the
body such as the lungs, digestive system, sweat glands and
reproductive organs. Although advances in the management
and care of CF patients have led to the majority surviving
into adulthood, cystic fibrosis still involves a complex, time-
consuming and, sometimes, difficult range of treatments,
limits and rules, and remains a progressive and ultimately
fatal multisystem disease with a heavy treatment regimen
[3]. This leads to new challenges for people with the disease,
their families and the medical teams who care for them. As
life expectancy has improved and daily treatments haveed by Elsevier B.V. All rights reserved.
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patients' health-related quality of life (HRQoL) has assumed
a growing importance [4] and understanding whether this
longevity has added “quality years” to the lives of CF
patients is a question which needs to be addressed [5].
Health-related quality of life measurement is important in
determining the impact CF has on the person's ability to live
a fulfilling life [6]. It can complement clinical measures of
disease status. Traditional clinical measures such as
respiratory function tests and body mass index assessment
are important but they do not capture the broader impact of
the disease [7]. Generic HRQoL measures have been used
because they allow comparison with a healthy population or
between different conditions, and because they may detect
quality of life issues that were not previously thought to be
problematic [8]. However, generic HRQoL measures are not
sufficiently specific for a CF population. A few CF specific
assessment instruments have been developed or evaluated in
different countries in the last 10 years, in an attempt to better
understand CF specific issues in clinical practice and
research [8–16]. One of these tools is the Cystic Fibrosis
Quality of Life Questionnaire (CFQoL) [16], a health-related
quality of life instrument for adults and adolescents (age
≥14 years) with cystic fibrosis, developed in the UK. The
CFQoL is a patient derived measure which includes domains
and response scales that have been determined by people
with CF and are therefore meaningful to them. The measure
includes domains which concern the wider impact on
patients' lives (e.g. interpersonal relationships, career issues
and future concerns) not found in other CF specific scales.
Cross-cultural validation of an existing valid and reliable
HRQoL measure has the advantage of avoiding the time-
consuming initial stages of development of a new question-
naire, and allows researchers to choose the measure they are
going to validate after considering their own requirements
and the psychometric properties of the instrument. This work
aimed to 1) translate the original English CFQoL Question-
naire into Italian and evaluate the linguistic translation and 2)
to psychometrically evaluate the Italian version of the
CFQoL Questionnaire in the Italian CF population.
2. Methods
2.1. Linguistic validation
A translated questionnaire needs to demonstrate “equiv-
alence” with the original in order to permit a valid
comparison of any data derived from them. The linguistic
validation of the CFQoL followed the international guide-
lines suggested by Guillemin et al. [17] and by the MAPI
Research Institute [18], and was carried out through the
following steps. 1) Two independent forward translations
from English into Italian were produced by two professional
translators. 2) A first review of these two raw versions was
done independently by three medical doctors (a CF
Paediatrician, a Pulmonologist and a Generic MedicalDoctor) who indicated the clarity of each item, and when
provided with different ways of translation indicated the
most understandable sentence/word. 3) The CF research
team merged the two raw versions to create the first raw
Italian version. 4) Two new backward translations from
Italian to English were undertaken by two native speaking
English persons who had been living in both an English
speaking country and Italy long enough to know the
languages, the habits and the routine daily life of each
culture. 5) The CF research team, with the collaboration of
two people from the CF team who developed the original
CFQoL compared the backward English version to the
original English one. 6) The comparison with the original
CFQoL led to the second raw translation into Italian. 8) The
Italian CF research team and the English CF research team
met a few times to discuss and resolve semantic and
conceptual discrepancies and produced the final Italian
version of the CFQoL Questionnaire.
Finally, face validity was assessed. Testing the face or
content validity of a questionnaire evaluates whether the
questionnaire appears to measure what it is meant to, and that
it is acceptable to people with CF. Consecutive out-patients
attending the CF Centre in Cesena were administered the
Italian CFQoL. They were interviewed as to the clarity of
each item and concept, the clarity of the response options and
the risk of misunderstanding the questions.
2.2. Psychometric evaluation
This involved determining the construct validity, internal
reliability, concurrent validity, known groups validity and
test–retest reliability of the Italian CFQoL. Statistical
analyses were undertaken using the Statistical Package for
Social Science (SPSS version 12.0).
2.2.1. Participants and procedure
Ethical approval was obtained to conduct the research in
all CF Units. All CF patients, aged ≥14 years, with a
confirmed diagnosis of cystic fibrosis, attending one of the
four regional Cystic Fibrosis Centres (Cesena, Parma, Trieste
and Grosseto) were considered eligible for the study. Patients
were enrolled in the study during a Day-Hospital (DH)
routine visit if they were clinically stable, as determined by
the CF medical team. They were administered both the
Italian CFQoL Questionnaire and the Italian Short-Form
Health Survey (SF-36) [19–22]. After 2 weeks, participants
were asked to complete the CFQoL again and return it by
post.
2.2.2. Measures
The Cystic Fibrosis Quality of Life Questionnaire is a
health-related quality of life measure consisting of 52 items
across nine domains (physical functioning, social function-
ing, treatment issues, chest symptoms, emotional function-
ing, concerns for the future, interpersonal relationships, body
image, career concerns). Responses to the questionnaire are
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on a 0 to 100 point scale, where the higher scores represent a
better quality of life (scores of b50 represent negative scores,
suggesting that the individuals may be experiencing
difficulties within that particular domain). In the original
English version, the instrument demonstrated a robust factor
structure, strong internal consistency, good concurrent
validity when compared with the SF-36 health survey, and
good discriminatory ability between patients with different
levels of disease severity. Test–retest reliability at 10 days
was also found to be robust [16]. The CFQoL questionnaire
is brief enough to be applied in clinical settings (completion
time of about 10 min) and is simple to administer and score.
The SF-36 is a brief, yet comprehensive generic health-
related measure consisting of 36 items across eight domains
(physical functioning, role-physical, bodily pain, general
health, vitality, social functioning, role-emotional, mental
health). Scores are standardized on a 0 (worse possible health
state) to 100 (best possible health state) point scale, with
higher scores indicating a better quality of life. The SF-36
is the most used and established instrument to assess ge-
neric health state and has been shown to be reliable and valid
[19–22].
2.2.3. Factorial structure and homogeneity
Construct validity evaluates the robustness of the
structure of the measure and determines the domains or sub-
scales (e.g. physical function, chest symptoms) of the
questionnaire. The factorial structure was tested by principle
components analysis (PCA) with eigenvalues N1 on a
varimax rotation. Item to domain correlations were calculated
to evaluate the extent to which each item was associated with
its domain (or with another competing domain). Correlations
were regarded as acceptable if they were at least 0.3.
The internal reliability of each domain (the extent to which
items within a domain are conceptually related) was assessed
using Cronbach alpha coefficients. Coefficients show a good
internal reliability when the value is 0.7 or above [23].
2.2.4. Concurrent validity
It is typical to asses the concurrent validity of a new
instrument by comparing it with an established and validated
questionnaire. The medical outcomes survey Short Form-36
(SF-36) was used as a comparator. Correlation coefficients
were obtained for the comparable domains on the CFQoL
and SF-36 domains (physical functioning, social function-
ing, mental health/emotional functioning, total scores).
2.2.5. Known groups validity
The measurement of true construct validity is complex as it
is an on-going process of assessing whether the instrument
performs consistently with theoretical expectations. For
example, some HRQoL domains would be expected to
discriminate between levels of disease severity. In a complex
disease like CF, disease severity is difficult to define but it may
be defined by percentage predicted forced expiratory volumein 1 s (FEV1), or age (as increasing age is typically associated
with decreased survival). To assess whether the measure could
differentiate between patients according to their FEV1, patients
were divided into three groups according to the international
categorization: mild (FEV1≥71%), moderate (FEV1=41–
70%), severe (FEV1≤40%). For age, patients were also
divided into three groups: 14–19 years; 20–29 years and
30 years and over. One-way analyses of variance (ANOVA)
were employed to compare theCFQoL domain scores between
the three groups.
2.2.6. Test–retest reliability
The test–retest procedure measures the stability of the
CFQoL over time. If a repeat administration of the CFQoL is
given whilst the person's health status is stable, similar
scores should be obtained for each domain at both time
points. The time period of 2 weeks was chosen to be long
enough not to introduce memory confounds while being
short enough to avoid fluctuations in disease status.
Alongside the second administration of the CFQoL, patients
were sent a brief questionnaire which asked them whether
their health had changed since the first completion of the
measures. Using a scale of integers from −7 (negative scores
denoted worsening health) to +7 (positive scores denoted
better health) patients were asked to rate any changes over
the 2 weeks [7=changed a very great deal, 6=a great deal,
5=a good deal, 4=moderately, 3=somewhat, 2=a little,
1=almost the same, 0=no change] [24]. Only patients who
scored −1, 0 or +1, reporting ‘no change’ or ‘almost the
same’, and who completed the questionnaires within 14 days
were included. Test–retest reliability was assessed by com-
puting intraclass correlation coefficients (ICC).
3. Results
3.1. Linguistic validation
The acceptability and face validity of the questionnaire
was confirmed by positive comments from the CF team and
people with CF. Fifteen consecutive patients reported that the
items were relevant for people with CF and there were no
items, or response options that were difficult to understand.
The Italian CFQoL took approximately 10 min to complete.
The acceptability of the instruments is also confirmed by the
lack of missing data in the psychometric evaluation. Only one
participant had one missing response in the whole data set.
3.2. Psychometric validation
Between 2003 and 2005, 120 patients were recruited and
gave written informed consent and assent. The sample com-
prised 64 males and 56 females (37 adolescents aged 14 to
19 years and 83 adults), with a mean age of 25.38 (SD=7.64,
range=14–46 years). Mean FEV1 and BMI were 68.02%
(range = 17–124%) and 20.84 (range = 13.90–36.00)
respectively.
Table 1
Factorial structure and internal reliability of the Italian CFQoL
PF SF TI CS ER FC IR BI CI
Cronbach alpha coefficients 0.90 0.86 0.81 0.91 0.90 0.90 0.90 0.73 0.76
PF1 0.66 0.43 0.02 0.13 −0.05 0.18 0.12 −0.05 0.09
PF2 0.88 −0.01 0.06 0.05 0.10 0 0 0.27 0.08
PF3 0.90 0.01 0.19 −0.01 −0.07 −0.02 −0.01 0.13 −0.01
PF4 0.86 −0.18 0.10 −0.07 −0.02 −0.07 0.05 0.230 0.04
PF5 0.82 0.06 0.10 0.01 −0.23 −0.20 0.13 −0.03 0.09
PF6 0.25 −0.02 0.14 0.07 0.67⁎ −0.07 0.11 0.04 0
PF7 0.50 0.17 −0.16 0.09 0.29 −0.01 0.09 −0.04 0.03
PF8 0.69 0.29 −0.15 0.26 0.20 0.15 0.08 0.01 0.07
PF9 0.73 0.16 0.12 0.26 0.27 0.19 0.08 −0.02 0.10
PF10 0.73 0.19 0.16 0.30 0.23 0.16 0.12 0.08 0.09
SF1 −0.21 0.60 0.07 0.27 0.23 0.14 0.38 0.04 0.04
SF2 −0.10 0.69 0.02 0.27 0.19 0.07 0.23 −0.33 0
SF3 0.03 0.71 −0.03 0.24 0.23 0.12 0.21 −0.28 0.04
SF4 −0.12 0.38 0.22 0.46⁎ −0.02 0.13 0.51⁎ −0.02 0.17
TI1 0.22 0.14 0.75 0.29 0.12 0.19 0.05 0.06 0.11
TI2 0.38 0 0.59 0.40 0.05 0.04 −0.01 −0.13 0.21
TI3 0.54⁎ −0.15 0.36 0.47⁎ 0.03 0.07 −0.12 0.21 0.13
CS1 0.64⁎ 0.28 0.17 0.40 0.02 0.23 0.16 0.03 −0.03
CS2 0.53 0.03 0.21 0.61 −0.04 0.15 0.11 0.06 −0.04
CS3 0.31 0.07 0.15 0.77 −0.13 0.089 0.21 −0.023 −0.05
CS4 0.57 0.06 0.20 0.61 0.01 0.07 0.12 0.19 0.11
ER1 0.29 −0.31 −0.01 0.16 0.68 0.06 0 0.04 0.32
ER2 0.08 −0.07 −0.02 0.23 0.73 0.15 0.12 0.21 0.21
ER3 0.03 0.07 0.13 0.13 0.77 0.15 0.07 0.13 −0.04
ER4 0.23 0.13 0.12 0.23 0.68 0.04 0.25 −0.03 0.26
ER5 0.60⁎ 0.02 −0.09 0.04 0.54 0.13 0.12 0.09 0.02
ER6 0.40 0 0.01 0.18 0.51 0.10 0.35 0.14 0.01
ER7 0.37 0.02 0.16 0.18 0.64 0.12 0.15 0.12 0.17
ER8 −0.01 0.07 0.17 0.28 0.54 0.47 −0.02 −0.01 0.14
FC1 −0.02 −0.03 0.01 0.26 −0.02 0.77 0.14 0.04 0.04
FC2 0.16 0.08 0.01 0.07 0.07 0.75 0.26 0.00 0.08
FC3 0.09 −0.15 0.08 0.10 0.07 0.87 0.11 0.06 0.17
FC4 0.12 0.05 0.06 0.22 −0.02 0.72 0.08 0.15 0.26
FC5 −0.12 0.11 0 0.40 −0.12 0.60 0.30 0.08 0.10
FC6 0.01 0.09 0.05 0.47⁎ −0.04 0.44 0.36 0.17 0.22
IR1 0.03 −0.09 0.05 0.42 −0.04 0.12 0.71 0.06 0.11
IR2 0.09 −0.12 −0.10 0.26 −0.13 0.26 0.50 0.06 0.36
IR3 0.18 −0.15 −0.04 0.19 0.042 0.13 0.70 0.25 0.28
IR4 0.20 0.06 −0.04 0.03 0.13 0.17 0.81 0.2 0.13
IR5 0.31 0.17 0.01 −0.05 0.20 0.17 0.70 −0.04 0.18
IR6 −0.03 0.26 0.23 0.35 0.10 0.24 0.51 0.14 0.30
IR7 0.15 0.08 −0.06 0.37⁎ 0.39⁎ 0.12 0.30 0.40⁎ 0.14
IR8 0.12 0.36⁎ 0.34⁎ 0.24 0.30 0.19 0.35 0.08 −0.04
IR9 0.22 0.17 −0.04 0.12 0.26 0.27 0.33 0.14 0.18
IR10 0 0.18 0.28 0.51⁎ 0.14 0.24 0.47 0.19 0.24
BI1 0.13 −0.10 0.10 0.23 0.16 0.24 0.01 0.55 −0.02
BI2 0.17 0.28 −0.14 0.05 −0.14 0.2 0.30 0.60 −0.05
BI3 0.03 0.04 0.08 0.26 0.10 0.01 0.23 0.81 0.20
CI1 0.09 0.10 0.10 0.09 −0.02 0.25 0.30 −0.02 0.78
CI2 0.130 0.03 0.12 0.12 0.11 0.22 0.29 0.08 0.78
CI3 0.21 0.73⁎ 0.09 −0.04 0.01 −0.09 −0.04 0.12 0.18
CI4 0.05 0.19 0.05 0.32 −0.03 0.11 0.24 0.15 0.66
Correlations with own domain are in bold print. ⁎Correlations with unrelated domains that are similar to or greater than intradomain correlations. PF = physical
functioning. SF = social functioning. TI = treatment issues. CS = chest symptoms. ER = emotional responses. FC = future concerns. IR = interpersonal
relationships. BI = body image. CI = career issues.
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The solution that emerged from the PCA highlighted 9
domains and accounted for 72% of the overall variance within
the data set. The factorial structure was found to be essentiallysimilar to the original one, even if a few items did not show
strong correlation with their factor. The internal reliability was
found to be robust, with Cronbach alpha values between 0.73
and 0.91. Item to domain correlations were good and are
Table 2
CFQoL summary data, floor and ceiling effects
CFQoL
domains
Mean (SD; range) Floor effects
(% minimum
score of 0)
Ceiling effects
(% maximum
score of 100)
Physical
functioning
86.13 (16.74; 10–100) 0.0 15.8
Social
functioning
87.17 (18.42; 0–100) 0.8 35.0
Treatment
issues
75.00 (22.31; 0–100) 2.5 15.0
Chest
symptoms
75.33 (23.17; 0–100) 0.8 12.5
Emotional
responses
80.19 (17.57; 15–100) 0.0 5.8
Concerns for
the future
54.81 (27.64; 0–100) 1.7 7.5
Interpersonal
relationships
73.39 (20.12; 16–100) 0.0 5.8
Body image 77.50 (23.42; 20–100) 0.0 33.3
Career
concerns
75.92 (21.66; 15–100) 0.0 25.0
Table 4
Mean (SD) CFQoL scores by age
Domains 14–19 years
(n=37)
20–29 years
(n=53)
N29 years
(n=30)
Physical functioning 90.91 (9.0) 90.04 (8.9) 72.81 (25.8)
Social functioning 93.71 (7.5) 89.50 (12.3) 74.44 (29.4)
Treatment issues 80.19 (17.5) 74.80 (21.1) 68.89 (28.6)
Chest symptoms 82.00 (17.7) 73.90 (22.0) 67.22 (29.3)
Emotional responses 86.93 (13.8) 76.55 (17.4) 77.04 (20.4)
Concerns for the future 69.05 (27.08) 45.33 (22.4) 48.89 (29.3)
Interpersonal relationships 81.72 (17.7) 70.96 (18.5) 67.26 (22.2)
Body image 79.43 (23.0) 75.87 (23.2) 82.47 (20.7)
Career concerns 85.43 (18.6) 73.90 (20.8) 65.56 (22.5)
120 F. Monti et al. / Journal of Cystic Fibrosis 7 (2008) 116–122presented in Table 1 together with the Cronbach alpha
coefficients. For each domain, CFQoL summary data and
floor and ceiling effects are given in Table 2.
3.2.2. Concurrent validity
The comparable domains of the CFQoL and the SF-36
correlated well. All the correlations were moderate to strong
(physical functioning r=0.73, social functioning r=0.68,
emotional functioning r=0.70) and very highly significant
(all p'sb0.001), indicating that the CFQoL has good
concurrent validity.
3.2.3. Known groups validity
Domain comparisons between the three FEV1 groups
demonstrated a significant main effect for physical func-
tioning (F=4.55, pb0.01), where CF patients with mild
disease reported statistically significantly higher scores than
patients in both the moderate and severe groups. Mean
CFQoL domain scores are presented for the three FEV1%
predicted groups in Table 3. Except for treatment issues and
body image, domain comparisons between the three age
groups indicated that the older adults reported a poorerTable 3
Mean (SD) CFQoL scores by FEV1% predicted
Domains FEV1≥70%
(n=52)
FEV1=40–
69% (n=46)
FEV1b40%
(n=22)
Physical functioning 91.32 (8.2) 83.14 (19.6) 80.11 (20.5)
Social functioning 90.43 (13.9) 83.57 (24.2) 85.83 (12.3)
Treatment issues 76.87 (22.6) 71.58 (24.0) 77.40 (19.0)
Chest symptoms 78.94 (21.4) 71.31 (24.8) 69.72 (22.8)
Emotional responses 80.95 (18.0) 78.03 (18.7) 79.30 (14.0)
Concerns for the future 51.98 (30.0) 53.49 (25.3) 52.96 (28.2)
Interpersonal relationships 75.79 (17.9) 71.14 (19.2) 68.78 (26.0)
Body image 81.27 (21.7) 77.77 (22.5) 74.44 (24.1)
Career concerns 76.28 (21.6) 74.17 (21.8) 72.78 (23.7)quality of life in comparison with the younger groups:
physical functioning (F=14.47, pb0.001); social function-
ing (F=10.54, pb0.001); chest symptoms (F=3.27,
pb0.04); emotional responses (F=4.26, pb0.02); future
concerns (F=9.21, pb0.001); interpersonal relationships
(F=5.05, pb0.01); career concerns (F=7.39, pb0.001).
Mean CFQoL domain scores are given for the three age
groups in Table 4.
3.2.4. Test–retest reliability
Eighty-nine patients completed a repeat CFQoL and
reported that their health had remained stable over 2 weeks.
Table 5 presents the ICC and 95% confidence interval for
each domain. Good test–retest reliability was observed for
each domain of the CFQoL.
4. Discussion
The aims of this work were to translate the original English
CFQoL Questionnaire into Italian, evaluate the linguistic
translation and psychometrically evaluate the Italian version of
the CFQoLQuestionnaire.With a representative sample of the
Italian CF population [2], the Italian CFQoL has demonstrated
a robust factor structure and internal reliability. The factor
structure is basically the same as the UK version, with just a
few items showing weaker item to domain correlations. This
may be expected given that the CFQoL was developed in the
UK. Essentially, the Italian CFQoL has been shown to possess
good face, content, construct and concurrent validity. It is
internally reliable, reliable over time and able to discriminateTable 5
Test–retest reliability of the Italian CFQoL
Domains Interclass correlation coefficients (95% CI)
Physical functioning 0.97 (0.95, 0.98)
Social functioning 0.83 (0.74, 0.88)
Treatment issues 0.94 (0.91, 0.96)
Chest symptoms 0.93 (0.90, 0.96)
Emotional responses 0.95 (0.93, 0.97)
Concerns for the future 0.96 (0.93, 0.97)
Interpersonal relationships 0.98 (0.96, 0.98)
Body image 0.97 (0.95, 0.98)
Career concerns 0.95 (0.92, 0.97)
121F. Monti et al. / Journal of Cystic Fibrosis 7 (2008) 116–122between some known groups based on theoretical expecta-
tions. Clinical data are diagnostically essential and crucial for
patient monitoring, but it may be argued that clinical
information is insufficient for whole patient care and
management. The person with CF usually brings with them
a much more complex situation in relation to their health
cognitions and behaviours. Results from the Italian CFQoL
will provide patient reported data on the wider aspect of how
CF impacts on a person's life and will complement traditional
clinical data.
The measurement of true construct validity is complex as
it is an on-going process of assessing whether the instrument
performs consistently with theoretical expectations. The
CFQoL was able to discriminate between groups based on
physical functioning, with those in the least severe group
reporting a better HRQoL than those in the moderate and
severe groups. Although not statistically significant, there
were clinically meaningful differences [25] on several other
domains (social functioning, treatment issues, chest symp-
toms, interpersonal relationships and body image) consistent
with the hypothesis that more severe disease, as measured by
FEV1, would be associated with poorer reported HRQoL.
There are several possible explanations as to why statistical
significance was not reached with these domains. Sub-group
numbers were small, especially for those with severe disease.
Alternatively, FEV1 may no longer be the most appropriate
‘global’ measure of disease severity. The increase in
diabetes, B. cepacia, osteoporosis, liver disease and other
complications associated with CF longevity may complicate
the association between FEV1 and disease severity. The age
group data, however, was consistent with theoretical
expectation, that age is typically associated with progressive
disease. The older group reported the poorest HRQoL for all
domains except treatment issues and body image.
The data do not allow for formal, direct comparison with
the original UK data due to potentially confounding cultural
differences and a different time point in the ‘evolution’ of CF
disease and management. As a disease, CF has changed
considerably in the 10 years since the UK instrument was
developed. People are surviving longer but there has also
been an increase in CF complications (e.g. diabetes, liver
disease and osteoporosis). In both the UK and Italian data the
mean age (with similar age range) was approximately
25 years. The range of FEV1 predicted values were similar
but the mean values were different (UK 55%; IT 68%),
indicating a less severe Italian sample. Given the possible
confounds, data interpretation is difficult, but it is worth
noting that for some CFQoL domains the mean scores were
similar (physical, social and emotional function and treatment
issues) but for future concerns, career issues, interpersonal
relationships, body image and chest symptoms, a better
HRQoL was reported in the current Italian data, which may
reflect an optimism for a better, longer adult life [26–28].
The Italian CFQoL Questionnaire has been shown to be a
valid and reliable measure. The measure is appropriate for
several different applications. It may be employed duringconsultations, clinic review or such as transplant review to
guide decision making. As all the items are relevant to CF it
can provide a broader assessment of the person's health
situation and aid the multidisciplinary CF team in identifying
problem areas which may need a specific intervention. The
nine domains of the CFQoL are independent scales which,
together provide a profile of a person's HRQoL. Therefore,
individuals can be assessed on a domain or item basis if there
are specific difficulties to address. In many cases, having a
measure like the CFQoL, allows the patient to think about his
own needs and to communicate to the CF team, not only his
concerns about treatments and clinical issues but also his
psychosocial concerns. Additionally, as the CFQoL Ques-
tionnaire is a specific CF health-related measure it may help
both the patient and the CF team to face some specific topics.
We must also highlight that having a specific tool to better
understand people with CF may be extremely important in
the management of treatment regimens. A number of studies
have investigated factors affecting adherence to treatment in
CF. Early research tended to focus on demographic and
clinical variables but recent work has demonstrated that there
are multiple factors to determinate adherence, such as
personal perception of health status, coping style, worries,
social reasons, motivation and side effects of treatments [29–
31]. The questionnaire is also suitable for cross-sectional
studies where group comparisons are being made. Currently,
we do not have data regarding sensitivity to change over
time, so it is not possible to estimate clinically important
differences. However, the results of the test–retest reliability
analyses demonstrate the excellent stability of the instrument
and this provides the foundation for the evaluation of
responsiveness to change in longitudinal research and
clinical practice. Research concerning HRQoL in cystic
fibrosis in Italy needs further investigations. The validation
of the Italian version of CFQoL represents a first attempt to
get closer to this important issue.
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